Brigham and Women's Hospital, Harvard Medical School, Boston, Massachusetts, USA.
Antimicrob Agents Chemother. 2012 Nov;56(11):5998-6000. doi: 10.1128/AAC.01217-12. Epub 2012 Aug 13.
HIV-1 resistance testing was performed in 47 antiretroviral (ARV)-treated subjects with low-level viremia (LLV) of <1,000 copies/ml. The median viral load was 267 copies/ml. In those with ≥2 LLV episodes, 44% accumulated additional resistance mutations. Fewer active ARVs and longer elapsed time were associated with an increased risk of resistance accumulation after controlling for adherence and viral load. Virologic failure followed 16% of LLV time points. Strategies for early intervention after LLV episodes should be further studied.
对 47 名接受抗病毒药物治疗且病毒载量（VL）较低（<1000 拷贝/ml）的患者进行了 HIV-1 耐药性检测。中位病毒载量为 267 拷贝/ml。在那些有≥2 次低病毒载量血症（LLV）发作的患者中，44%的患者累积了额外的耐药突变。在控制了依从性和病毒载量后，较少的有效抗病毒药物和更长的时间间隔与耐药积累的风险增加相关。16%的低病毒载量时间点出现了病毒学失败。应进一步研究 LLV 发作后早期干预的策略。
